Relationship between neuropilin-1 expression and prognosis, according to gastric cancer histology

• Published in: Journal of molecular histology 2020-04, Vol.51 (2), p.199-208
• Main Authors: Seo, Ho Seok, Hyeon, Jiyeon, Song, In Hye, Lee, Han Hong
• Format: Article
• Language: English
• Subjects: Aged; Biomarkers, Tumor; Biomedical and Life Sciences; Biomedicine; Cell Biology; Developmental Biology; Female; Gastrectomy; Gastric cancer; Gene Expression; Histology; Humans; Immunohistochemistry; Life Sciences; Male; Medical prognosis; Middle Aged; Multivariate analysis; Neoplasm Staging; Nerve growth factor; Neuropilin; Neuropilin-1 - genetics; Neuropilin-1 - metabolism; Original Paper; Patients; Prognosis; Stomach Neoplasms - genetics; Stomach Neoplasms - metabolism; Stomach Neoplasms - mortality; Stomach Neoplasms - pathology; Survival; Survival Analysis; Therapeutic applications; Tumor Burden; Tumor markers; Tumors
• ISSN: 1567-2379; 1567-2387
• DOI: 10.1007/s10735-020-09870-z

Neuropilin-1 (NRP-1) is known to be related to various types of cancer and is considered a novel tumor marker or therapeutic target. The aim of this study was to identify the clinical implications of NRP-1 expression in terms of prognosis in patients with gastric cancer. A total of 265 patients who underwent radical gastrectomy for the treatment of gastric cancer from 2008 to 2011 were included in this retrospective study. NRP-1 expression of tumors was determined by immunohistochemistry. The patients’ clinicopathological characteristics, operative details, and long-term outcomes were retrospectively analyzed. A total of 181 (68.3%) patients demonstrated expression of NRP-1. No survival difference was observed according to NRP-1 expression in any patient. The patients were divided into the gland formation (GF) and the no gland formation (nGF) types, according to histology. NRP-1 expression rates were 65.6% (84/128) and 70.8% (97/137), respectively. NRP-1 expression was not an independent prognostic factor in the GF group, although patients who expressed NRP-1 had better survival outcomes. In contrast, patients who expressed NRP-1 in the nGF group had worse 5-year survival rates ( p  = 0.027), and NRP-1 was an independent prognostic factor in a multivariate analysis (hazard ratio, 1.923; 95% confidence interval, 1.041–3.551). NRP-1 expression in patients with nGF type gastric cancer is predictive of a poor prognosis.